For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Olema Pharmaceuticals Shares Drop 15.1% After AstraZeneca Trial Results

Sep 17, 2026
Olema Pharmaceuticals Shares Drop 15.1% After AstraZeneca Trial Results

Olema (NASDAQ:OLMA) shares fell 15.1% in pre-market trading, dropping to $8.68, after disclosed that its Phase 3 SERENA-4 trial of camizestrant failed to meet its primary endpoint. AstraZeneca reported that the combination of camizestrant and palbociclib did not show a statistically significant improvement in progression-free survival for patients with ER-positive, HER2-negative advanced breast cancer.

This development has prompted investors to reassess the implications for Olema's lead candidate, palazestrant (OP-1250), which is currently being evaluated in the pivotal Phase 3 OPERA-01 trial. Palazestrant is an oral selective estrogen receptor degrader and complete estrogen receptor antagonist, sharing a similar mechanism with camizestrant. However, the outcome of AstraZeneca's trial does not directly influence the results of Olema's separate clinical program.

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

The SERENA-4 results come on the heels of Roche's persevERA trial, which also failed to meet its objectives in the first-line advanced breast cancer setting earlier this year. Following the AstraZeneca announcement, Stifel adjusted its price target for Olema, reducing it from $48 to $30 while maintaining a Buy rating.

Investors Await Key Trial Results Amidst Stock Volatility

Investors are now awaiting the top-line results from Olema's OPERA-01 Phase 3 trial, which will provide critical clinical data specific to palazestrant. Despite the recent decline, Olema shares were still trading above their 52-week low of $6.65, in contrast to a 52-week high of $36.26.

The pre-market decline in Olema's stock occurred during a broader downturn for U.S. equities, with the Nasdaq dropping 1.7% and the S&P 500 declining by 0.7%. The market's reaction to the SERENA-4 results and Stifel's price target adjustment reflects ongoing investor concerns regarding the potential impact on Olema's development program for palazestrant.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
Stock Market Outlook: Top Picks for November 16-20, 2026
Breaking Market News Nov 15, 2026

Stock Market Outlook: Top Picks for November 16-20, 2026

This article discusses stock market recommendations for the week of November 16-20, 2026, highlighting APL Apollo Tubes and Nykaa as top…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)